Jia JL , Han YH , Kim HC , Ahn M , Kwon JW , Luo Y , Gunasekaran P , Lee SJ , Lee KS , Kyu Bang J , Kim NH , Namgoong S .

	Figure 1. The presence of two Plk1-binding regions at the N terminus of mouse Emi2.(A) Diagram illustrating molecular events for cell cycle resumption after fertilization. In matured mammalian oocytes, maturation promoting factor (MPF) activity maintain high, because of ubiquitin ligase APC/C is inhibited by Emi2. After fertilization, increased Ca2+ activates calmodulin-dependent protein kinase II (CaMKII) and it phosphorylates N-terminal of Emi2. Plk1 is recruited by recognition of phosphothreonine residues in Emi2 by polo box domain (PBD) in Plk1 and subsequently phosphorylated Emi2 and phosphorylated Emi2 become substrate of another class of ubiquitin ligase, SCF and degradated by ubiquitin-proteasome. Activated APC-C can decrease MPF levels, therefore cell cycle for meiosis can be resumed. (B) Domain architecture of Emi2 and multiple-sequence alignment of Emi2 protein sequences from zebrafish (Danio rerio: Dan), Austrian ghostshark (Callorhinchus milii: Cal), Xenopus (Xenopus laevis: Xen), chicken (Gallus: Gal), Homo sapiens (hsa), pig (Sus scrofa: Sus), and mouse (Mus musculus: Mus). ZBR : Zinc Binding Region, Peptides containing a phosphorylated threonine (Emi2146–177 or Emi2169–177) are indicated with gray bars. Threonine residues that are subject to phosphorylation are indicated with a red box. (C) Binding affinity and binding stoichiometry of phosphorylated Emi2 peptides in relation to Plk1 Polo box domain (PBD). Isothermal titration calorimetry (ITC) with Emi2 peptides and Plk1-PBD was carried out as described in Materials and Methods. The dissociation constant (Kd) and the stoichiometric ratio of an Emi2 peptide to Plk1-PBD (n) is also shown. (D) Size exclusion chromatography coupled with multiangle light scattering (SEC-MALS) of PLK1-PBD·Emi2146–177 complexes. Plk1-PBD and the phosphorylated Emi2146–177 peptide were mixed at various stoichiometric ratios (molar ratio of Plk1-PBD1 to Emi2146–177: 1:1, 1:2, and 1:3, respectively) and were separated by size exclusion chromatography. The measured molecular weight of each peak is indicated with arrows.
	Figure 2. Crystal structure of Plk1 Polo box domain (PBD) and phosphorylated peptides derived from Emi2.(A) Domain organization of Plk1 and Emi2. Left: location of the kinase domain (KD) and the polo box domain (PBD) in Plk1 is indicated. Right: the location of the PBD-interacting part of Emi2 is highlighted in green. The phosphorylated threonine at amino acid positions 152 or 176 in Emi2 are also presented. ZBR: zinc-binding region. (B) Crystal structure of Plk1-PBD·Emi2146–177 (left) and Plk1-PBD·Emi2169–177. Plk1-PBD (blue) is shown as a cartoon Fig. and Emi2 fragments are shown as green sticks. Note that only electron density corresponding to amino acid residues 148–154 in Emi2146–177 is visible and was modeled. (C) Electrostatic surface representation (blue: positively charged, red: negatively charged) of Plk1-PBD bound to an Emi2-derived phosphopeptide. Left: Plk1-PBD·Emi2146–177, right: Plk1-PBD·Emi2169–177. (D) The surface of Plk1-PBD is colored according to residue conservation (conservation decreases from blue to red). Note that the Emi2-peptide binding regions including tyrosine-rich hydrophobic pockets and negatively charged regions binding Emi2156–169 are conserved (colored blue).
	Figure 3. Testing the interactions of Emi2 with Plk1 based on Emi2 degradation after pathernogenetic activation of oocyte.(A)Scheme of Emi21–300-mCherry reporter constructs used in the study. It contains Plk1 binding sites and degron required by recognition of SCF-mediated ubiquitinylation. Thr152, Phe169 and Thr176 mutated as alanine are indicated as red. After in vitro transcriptions, cRNAs were injected into MII oocyte and subjected to SrCl2-mediated parthenogenetic activation and decrease of fluorescence from mCherry was monitored by time-lapse imaging of oocytes. (B) Time-lapse microscopy of parthenogenetically activated oocyte injected with Emi21–300-mCherry cRNAs. WT: wild type Emi21–300-mCherry cRNAs; T152A: site-directed mutant Emi21–300-mCherry containing Threonine152 to Alanine substitution; F169A: Phenylalanine169 to Alanine substitution; T176A: Threone176 to Alanine substitution; Representative figures of each groups corresponding 5, 25, 45, 65, 85 and 105 min after SrCl2 treatment were shown. (C) Quantification of fluorescence from oocyte injected with Emi21–300-mCherry cRNAs. Normalized fluorescence from oocytes injected with wild type (Black, n = 7), T152A (Green, n = 6), F169A (Blue, n = 4) and T176A (Red, n = 5) at each time points (5 min interval) were measured and average of each time points were plotted. Error bars indicate standard error of mean (S.E.M).
	Figure 4. Peptidomimetics emulating the Plk1-PBD·Emi2 complex inhibit maturation of mouse oocytes.(A) Peptidomimetics resemble Plk1-PBD·Emi2 and bind to the Polo box domain (PBD) of Plk1. The compounds 103, 103-2, 103-5, 103-8, 103-10, 103-12, 103-13, 103-15 and 103-16 have been described previously34, and 699, 700, 701, 702, 703, 704, 705, 706 and 707 were characterized in this study. (B) Assessment of inhibitory activity of peptidomimetics on in vitro maturation (IVM) of mouse oocytes. Peptidomimetics were microinjected into immature mouse oocytes, which were subjected to IVM. GV: germinal vesicle, GVBD: germinal vesicle breakdown, MI: metaphase I, MII: metaphase II. Time (hr) required for maturation of an oocyte is indicated at the top of an arrow. Maturation status of mouse oocytes 12 hr after injection of a peptidomimetic was evaluated. At least three independent experiments were carried out and the ratios of oocytes at each developmental stage to all oocytes were plotted. Significant differences between the treatment groups and the control group are indicated by asterisk (***P ≤ 0.001, **P ≤ 0.01, *P ≤ 0.05). (C) Crystal structure of the Plk1-PBD·702 complex. PBD domain is shown in blue and peptidomimetic 702 is shown in green. In the enlarged circle, the structures of Emi2169–177 (violet) and peptidomimetic 702 (Green) are superimposed. Note that occupation of tyrosine-rich pockets by an alkylated imidazole ring (702) or a phenylalanine ring (Emi2169–177).
	Figure 5. The peptidomimetic 103-8 impairs oocyte maturation and delays parthenogenetic activation of mouse oocytes.(A) Effects of 103-8 injections on oocyte maturation. Control (oocytes injected with unphosphorylated BG34) and 103-8-injected oocytes were stained for PLK1 (red), α-tubulin (green), and DNA (blue). Bar = 20 μm. (B) Effects of 103-8 injections on parthenogenetic activation of mouse oocytes. Mature metaphase II (MII) oocytes were microinjected with a control compound (orange) or 103-8 (blue), and subjected to parthenogenetic activation by SrCl2. The progression of parthenogenetic activation was assessed by the formation of a pronucleus (examination under an inverted microscope). Statistical significance was tested by chi-square test (**P ≤ 0.01, *P ≤ 0.05, and N.S. P > 0.05). (C) Time-lapse microscopy of parthenogenetically activated oocyte injected with Emi21–300-mCherry cRNAs. Control: wild type Emi21–300-mCherry cRNAs injected with control BG34 control; 103-8: Emi21–300-mCherry cRNAs injected with 103-8 peptidomimetic; BI2536: Emi21–300-mCherry cRNAs injected and subjected to SrCl2 treatment in the presence of 100 nM BI2536. Bar = 40 μm. (D) Normalized fluorescence from oocytes injected with control (Black, n = 9), 103-8 (Red, n = 12) and BI2536 (Blue, n = 3) at each time points (5 min interval) were measured and average of each time points were plotted. Error bars indicate standard error of mean (S.E.M).

Adams, PHENIX: a comprehensive Python-based system for macromolecular structure solution. 2010, Pubmed

Adams, PHENIX: a comprehensive Python-based system for macromolecular structure solution. 2010, Pubmed
Ahn, A new class of peptidomimetics targeting the polo-box domain of Polo-like kinase 1. 2015, Pubmed
Arion, cdc2 is a component of the M phase-specific histone H1 kinase: evidence for identity with MPF. 1988, Pubmed , Xenbase
Bos-Mikich, Calcium oscillations and protein synthesis inhibition synergistically activate mouse oocytes. 1995, Pubmed
Bunkóczi, Phaser.MRage: automated molecular replacement. 2013, Pubmed
Capra, Predicting protein ligand binding sites by combining evolutionary sequence conservation and 3D structure. 2009, Pubmed
Chatot, An improved culture medium supports development of random-bred 1-cell mouse embryos in vitro. 1989, Pubmed
Ciceri, Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. 2014, Pubmed
Clift, Restarting life: fertilization and the transition from meiosis to mitosis. 2013, Pubmed
Elia, Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. 2003, Pubmed
Elia, The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. 2003, Pubmed , Xenbase
Emsley, Features and development of Coot. 2010, Pubmed
Erikson, A feedback loop in the polo-like kinase activation pathway. 2004, Pubmed , Xenbase
Fan, Characterization of Polo-like kinase-1 in rat oocytes and early embryos implies its functional roles in the regulation of meiotic maturation, fertilization, and cleavage. 2003, Pubmed
García-Alvarez, Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization. 2007, Pubmed
Gautier, Purified maturation-promoting factor contains the product of a Xenopus homolog of the fission yeast cell cycle control gene cdc2+. 1988, Pubmed , Xenbase
Gibson, Enzymatic assembly of DNA molecules up to several hundred kilobases. 2009, Pubmed
Hansen, CaMKII and polo-like kinase 1 sequentially phosphorylate the cytostatic factor Emi2/XErp1 to trigger its destruction and meiotic exit. 2006, Pubmed , Xenbase
Hyslop, Ca(2+)-promoted cyclin B1 degradation in mouse oocytes requires the establishment of a metaphase arrest. 2004, Pubmed
Isoda, Dynamic regulation of Emi2 by Emi2-bound Cdk1/Plk1/CK1 and PP2A-B56 in meiotic arrest of Xenopus eggs. 2011, Pubmed , Xenbase
Jang, Non-muscle tropomyosin (Tpm3) is crucial for asymmetric cell division and maintenance of cortical integrity in mouse oocytes. 2014, Pubmed
Jeong, Inhibition of Plk1 induces mitotic infidelity and embryonic growth defects in developing zebrafish embryos. 2010, Pubmed
Jones, Mammalian egg activation: from Ca2+ spiking to cell cycle progression. 2005, Pubmed
Jones, Ca2+ oscillations in the activation of the egg and development of the embryo in mammals. 1998, Pubmed
Kabsch, XDS. 2010, Pubmed
Li, Developments of polo-like kinase 1 (Plk1) inhibitors as anti-cancer agents. 2013, Pubmed
Liu, The anaphase-promoting complex/cyclosome inhibitor Emi2 is essential for meiotic but not mitotic cell cycles. 2006, Pubmed , Xenbase
Liu, New insight into metaphase arrest by cytostatic factor: from establishment to release. 2007, Pubmed
Liu, Calcium elevation at fertilization coordinates phosphorylation of XErp1/Emi2 by Plx1 and CaMK II to release metaphase arrest by cytostatic factor. 2005, Pubmed , Xenbase
Liu, Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel. 2011, Pubmed
Lorca, Calmodulin-dependent protein kinase II mediates inactivation of MPF and CSF upon fertilization of Xenopus eggs. 1993, Pubmed , Xenbase
Luo, PLK4 is essential for meiotic resumption in mouse oocytes. 2015, Pubmed
Lénárt, The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. 2007, Pubmed
Ma, Parthenogenetic activation of mouse oocytes by strontium chloride: a search for the best conditions. 2005, Pubmed
Madgwick, Mouse Emi2 is required to enter meiosis II by reestablishing cyclin B1 during interkinesis. 2006, Pubmed
Masui, Cytoplasmic control of nuclear behavior during meiotic maturation of frog oocytes. 1971, Pubmed
Murugan, Development of cyclic peptomer inhibitors targeting the polo-box domain of polo-like kinase 1. 2013, Pubmed
Nixon, Ca(2+) oscillations promote APC/C-dependent cyclin B1 degradation during metaphase arrest and completion of meiosis in fertilizing mouse eggs. 2002, Pubmed
Pahlavan, Characterization of polo-like kinase 1 during meiotic maturation of the mouse oocyte. 2000, Pubmed
Panchenko, Prediction of functional sites by analysis of sequence and structure conservation. 2004, Pubmed
Petronczki, Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1. 2008, Pubmed
Qian, The polo-like kinase Plx1 is required for activation of the phosphatase Cdc25C and cyclin B-Cdc2 in Xenopus oocytes. 2001, Pubmed , Xenbase
Rauh, Calcium triggers exit from meiosis II by targeting the APC/C inhibitor XErp1 for degradation. 2005, Pubmed , Xenbase
Sako, Emi2 mediates meiotic MII arrest by competitively inhibiting the binding of Ube2S to the APC/C. 2014, Pubmed , Xenbase
Solc, Multiple requirements of PLK1 during mouse oocyte maturation. 2015, Pubmed
Srinivasrao, Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1. 2014, Pubmed
Steegmaier, BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. 2007, Pubmed
Suzuki, Mouse Emi2 as a distinctive regulatory hub in second meiotic metaphase. 2010, Pubmed , Xenbase
Tong, Polo-like kinase-1 is a pivotal regulator of microtubule assembly during mouse oocyte meiotic maturation, fertilization, and early embryonic mitosis. 2002, Pubmed
Vanderheyden, Regulation of inositol 1,4,5-trisphosphate receptor type 1 function during oocyte maturation by MPM-2 phosphorylation. 2009, Pubmed
Xiong, Involvement of Polo-like kinase 1 in MEK1/2-regulated spindle formation during mouse oocyte meiosis. 2008, Pubmed
Yao, Polo-like kinase-1 in porcine oocyte meiotic maturation, fertilization and early embryonic mitosis. 2003, Pubmed
Yun, Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. 2009, Pubmed